NCT02772718View on ClinicalTrials.gov

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Hypoglycemia
Interventions
DRUG

XOMA 358 single dose level A

XOMA 358 single dose level A administered by intravenous infusion

DRUG

XOMA 358 single dose level B

XOMA 358 single dose level B administered by an intravenous infusion

DRUG

XOMA 358 single dose level C

XOMA 358 single dose level C administered by an intravenous infusion

DRUG

XOMA 358 multiple dose level 1

XOMA 358 multiple dose level 1 administered by an intravenous infusion

Trial Locations (5)

Unknown

Aurora

Chicago

Baltimore

Boston

Rochester

All Listed Sponsors
lead

XOMA (US) LLC

INDUSTRY

NCT02772718 - An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery | Biotech Hunter | Biotech Hunter